Citi Pharma becomes Pakistan’s largest antibiotics producer with new production technology from Xin Weisheng

LAHORE: Citi Pharma, a leading pharmaceutical manufacturer listed on the Pakistan Stock Exchange, has become Pakistan’s largest antibiotics producer, thanks to its strategic partnership with Chinese machinery specialist Xin Weisheng. The installation of automated aseptic production lines in its Phool Nagar facility has boosted manufacturing speed fivefold, transforming daily capacity from 10,000 to 100,000 vials.

This notable achievement comes amid Pakistan’s continued reliance on antibiotic imports—a challenge underscored by 2023 figures showing that over USD 126 million worth of antibiotics were imported, 84% of them from China. Citi Pharma’s enhanced domestic production significantly strengthens healthcare self‑reliance and resilience in the face of global supply disruptions Business Recorder.

Under the stewardship of Managing Director Dr. Zameer Ul Hassan, Citi Pharma has leveraged its reputation as one of the country’s largest API (Active Pharmaceutical Ingredients) manufacturers to secure its newfound market leadership citipharma.com.pk. Xin Weisheng’s director, Yuting Shao, expressed pride in contributing to Pakistan’s pharmaceutical independence: “Our partnership with Citi Pharma exemplifies how advanced manufacturing technology can transform a country’s healthcare capabilities.”

The partnership, which began in 2021, underscores how investment in cutting‑edge technology delivers direct benefits to public health and national economic stability. By scaling up local antibiotic production, Pakistan is gaining critical capacity to meet population needs independently—without relying on external suppliers.

Stay informed. Stay ahead.

CLICK HERE TO FOLLOW Medical News Pakistan WhatsApp Channel for trusted healthcare updates, expert insights, clinical research, policy news, and medical breakthroughs—delivered directly to you.